TARA Protara Therapeutics5.23+0.09 (+1.8%)
Premarket Decliner
TARA Protara Therapeutics7.43+0.59+8.6%
Premarket:6.70-0.73 (-9.8%)
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Globe NewswireMon, 23-Feb 5:05 PM
After Hours Decliner
After Hours:6.10-1.33 (-17.9%)
TARA Protara Therapeutics6.87+0.07+1.0%
Premarket:5.77-1.10 (-16.0%)
Protara Announces Pricing of $75 Million Public Offering
Globe NewswireThu, 4-Dec 10:03 PM
TARA Protara Therapeutics6.75+1.18+21.2%
After Hours:6.50-0.25 (-3.7%)
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
Globe NewswireTue, 18-Nov 4:30 PM
After Hours:6.64-0.11 (-1.6%)
